Decoy Therapeutics is trading at $1.13, up 9.71%, with its third-quarter update the clearest available catalyst; no source explicitly confirms it drove the pre-market rise. - The company issued the update before the open on November 3, reporting an optimized pan-coronavirus candidate with potential for once-weekly dosing in preclinical studies. - It expects to file a CTA or IND in the second half of 2027 and reported $8.1 million in cash as of September 30.